Neuroscience Letters 591 (2015) Christian Moritz, Francesco Berardi, Carmen Abate and Francesca Peri View Paper Post navigationPreviousPrevious post:Anavex Appoints Epilepsy and Clinical Trial Methodology Expert to Scientific Advisory BoardNextNext post:Anavex to Present at Sigma-1 Receptors SymposiumRelated PostsAnavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s DiseaseJuly 3, 2018The dual regulation of oxidative stress by SIGMA1 receptors in physiological or pathological conditionsApril 1, 2017Targeting M1 muscarinic and sigma-1 receptors in Alzheimer’s disease: Reversal of pathological hallmarks and associated cognitive dysfunction in McGill-R-Thy1-APP ratsMarch 30, 2017AF710B, a concomitant activator of M1 muscarinic and sigma-1 receptors: possible disease-modifying properties in McGill-R-Thy1-APP ratsMarch 14, 2016
Anavex Life Sciences Receives Approval To Initiate Phase 2b/3 Clinical Trial of ANAVEX®2-73 for the Treatment of Early Alzheimer’s DiseaseJuly 3, 2018
The dual regulation of oxidative stress by SIGMA1 receptors in physiological or pathological conditionsApril 1, 2017
Targeting M1 muscarinic and sigma-1 receptors in Alzheimer’s disease: Reversal of pathological hallmarks and associated cognitive dysfunction in McGill-R-Thy1-APP ratsMarch 30, 2017
AF710B, a concomitant activator of M1 muscarinic and sigma-1 receptors: possible disease-modifying properties in McGill-R-Thy1-APP ratsMarch 14, 2016
